AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|
10.5 C
New York
Sunday, November 8, 2026

Tag: development

newsFORsourcecompanycontentinformationreleases1market

Xinhua Silk Road: Posidonia China Night provides high-level platform for int’l maritime exchange, cooperation

BEIJING, June 8, 2026 /PRNewswire/ -- Posidonia China Night, held in Athens during the Posidonia 2026, one of the world's leading maritime exhibitions, brought...

Xinhua Silk Road: Posidonia China Night provides high-level platform for int’l maritime exchange, cooperation

BEIJING, June 7, 2026 /PRNewswire/ -- Posidonia China Night, held in Athens during the Posidonia 2026, one of the world's leading maritime exhibitions, brought...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

BLACKYAK Hosts “Himalayan Climate Charter 2026: Namche Summit” to Advance Global Climate Action

- Highlights the climate crisis facing the Himalayas and underscores the need for international solidarity and collective action- Held in Namche Bazaar, Nepal, the...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas 
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility

Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) -- Odysight.ai® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company’s financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company’s discretion to support business development and capitalize on market opportunities.

VolitionRx Announces Pricing of $4.6 Million Public Offering

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7,...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers